What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2026-03-31 compared with 2025-03-24 · 15 added, 36 removed, 29 unchanged (64% of the section changed)

13 unchanged sentences

Quarter ended March 31

of March 7, 2025, we had 453,373,806

shares of common stock, par value $0.001 per share, issued and outstanding, which were held by approximately 232 shareholders of

Our transfer agent is Pacific Stock Transfer, 6725 Via Austi Pkwy, Suite 300, Las Vegas, NV 89119.

of March 30, 2026, we had 482,688,356 shares of common stock, par value $0.001 per share,

issued and outstanding, which were held by approximately 232 shareholders of record.

Our transfer agent is Pacific Stock Transfer,

6725 Via Austi Pkwy, Suite 300, Las Vegas, NV 89119.

Authorized for Issuance Under Equity Compensation Plans

1 unchanged sentence

approved by stockholders and equity compensation plans not previously approved by stockholders.

Compensation Plan Information

of securities to be issued upon exercise of outstanding options, warrants and rights

Weighted-average

exercise price of outstanding options, warrants and rights

of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))

Equity Compensation Plan Information

Plan Category

Number of securities to be issued upon exercise of outstanding options, warrants and rights

Weighted-average exercise price of outstanding options, warrants and rights

Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))

Equity compensation plans approved by stockholders

3 unchanged sentences

authorized for issuance in exchange for consideration in the form of goods or services of certain individuals.

Omnibus Securities and Incentive Plan

October 2015, our Board of Directors and stockholders approved the adoption of the 2015 Omnibus Securities and Incentive Plan (the “ 2015

The 2015 Plan authorizes a pre-determined number of shares of common stock for issuance to all employees of the Company

or any subsidiary of the Company, any non-employee director, consultants and independent contractors of the Company or any subsidiary,

and any joint venture partners (including, without limitation, officers, directors and partners thereof) of the Company or any subsidiary.

The aggregate number of shares that may be issued under the Plan shall not exceed twenty percent (20%) of the issued and outstanding

shares of common stock on an as converted primary basis on a rolling basis.

For calculation purposes, the As Converted Primary Shares

(as defined in the 2015 Plan) shall include all shares of common stock and all shares of common stock issuable upon the conversion of

outstanding preferred stock and other convertible securities, but shall not include any shares of common stock issuable upon the exercise

of options, warrants and other convertible securities issued pursuant to the 2015 Plan.

As of December 31, 2024, the Converted Primary

Shares calculation results in 32,836,047 aggregate shares that may be issued under the 2015 Plan.

The 2015 Plan is administered by the

Company’s Compensation Committee, who may issue awards in the form of stock options and/or restricted stock awards.

Effective December

31, 2024, an aggregate total of 88,174,761 restricted stock units (“ RSUs ”) under the 2015 Plan were authorized, but

as of March 7, 2025, an aggregate total of 56,050,000 RSUs had been issued.

Sales of Unregistered Securities

4 unchanged sentences

During the Quarter Ended December 31, 2025

November 12 and 14, 2024, the Company completed the sale of 11,950,000 shares of common stock pursuant to its Regulation A+ offering,

conducted under the Company’s offering statement on Form 1-A, originally filed with the SEC on June 28, 2024 (File No.

(the “ Offering Statement ”), qualified by the SEC on July 16, 2024, as supplemented from time to time (the “ Regulation

A+ Offering ”).

November 20, 2024, 122,500 shares of common stock were issued to consultants for the sale of common shares pursuant to the Regulation

A+, and on December 31, 2024, the Company issued 42,049 common shares to consultants of the Company pursuant to their agreement.

December 2024, the Company issued 8,416,554 common shares in the exercise of warrants.

October 14, 2024, 250,000 shares of common stock were issued in connection with the vesting of restricted stock units.

December 16, 2024, 200,000 shares of Series B Preferred shares were converted into 2,500,000 shares of common stock.

December 2025, the Company issued 329,281 shares of Common Stock for services rendered in the amount of $22,687 and issued 500,000 shares

of Common Stock upon the vesting of RSUs.

Subsequent to December 31, 2025

February 6, 2025, there has been 12,500,000 shares of common stock issued under the Regulation A+.

January 2026, the Company issued 44,118 shares of common stock for services rendered.

In March 2026, the Company raised

$1,553,000 through the sale of 19,200,000 shares of Common Stock through the Regulation A+ Offering and concurrent private placement of

17,000,000 warrants.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity